FDA Clocks Review Time for WINREVAIR Breathing Aid Patent
Published Date: 7/2/2025
Notice
Summary
The FDA has officially set the review period for WINREVAIR, a medicine that helps people breathe better. This means the company can ask for extra time on their patent to protect their invention. If approved, this extension could give them more years to sell WINREVAIR without competition, which might affect when generic versions can appear.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Company Can Seek Patent Extension
The FDA has set the regulatory review period for WINREVAIR, which lets the company ask the U.S. Patent and Trademark Office for extra patent time to protect the product. This formal determination is a step that enables the company to seek an extension of its patent on WINREVAIR.
Possible Delay in Generic Competition
If the company’s patent extension is approved, WINREVAIR could get more years to be sold without competition. That extra exclusivity might affect when generic or biosimilar versions can appear on the market.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in